LMF Acquisition Opportunities company info

What does LMF Acquisition Opportunities do?
SeaStar Medical Holding (NASDAQ:ICU) is a medical device company developing a platform therapy to combat the harmful effects of excessive inflammation on vital organs. Their focus is on creating solutions that transform key immune system messengers into reparative signals or removing inflammatory mediators entirely. SeaStar's technology is still under development, targeting various areas like acute kidney injury and heart failure. The company aims to improve patient outcomes by mitigating the long-term consequences of inflammation on vital organs.
LMF Acquisition Opportunities company media
Company Snapshot

Is LMF Acquisition Opportunities a public or private company?

key
Ownership
Public

How many people does LMF Acquisition Opportunities employ?

people
Employees
12

What sector is LMF Acquisition Opportunities in?

pie chart
Sector
Health Care

Where is the head office for LMF Acquisition Opportunities?

location pin
Head Office
Denver, United States

What year was LMF Acquisition Opportunities founded?

founded flag
Year Founded
1994
What does LMF Acquisition Opportunities specialise in?
/Special Purpose /Acquisition Company /Public Equity /Merger Target /Business Combination /Public Listing

What are the products and/or services of LMF Acquisition Opportunities?

Overview of LMF Acquisition Opportunities offerings
Selective Cytopheretic Device (SCD): This is their proprietary technology in development. It's a blood purification device designed to target and remove or modify inflammatory mediators from a patient's bloodstream.
Cytokine Removal/Modification Therapy: SeaStar is researching and developing this therapy using the SCD to address the negative effects of excessive inflammation.
Clinical Research: They conduct clinical trials to evaluate the safety and efficacy of their SCD technology in various patient populations.
Partnerships: SeaStar might collaborate with other healthcare institutions or companies to accelerate development or commercialization of their therapy.
Regulatory Approvals: They seek regulatory approvals from agencies like the FDA to allow their technology for clinical use.
Public Awareness: SeaStar may engage in activities to raise awareness about the potential of their technology in the medical field.

Who is in the executive team of LMF Acquisition Opportunities?

LMF Acquisition Opportunities leadership team
  • Mr. Eric  Schlorff
    Mr. Eric Schlorff
    CEO, President & Executive Director
  • Dr. H. David Humes M.D.
    Dr. H. David Humes M.D.
    Co-Founder and Managing Director
  • Colonel Kevin  Chung FACP, M.D.
    Colonel Kevin Chung FACP, M.D.
    Chief Medical Officer
  • Mr. David A. Green CPA, M.B.A.
    Mr. David A. Green CPA, M.B.A.
    Chief Financial Officer
  • Tom  Mullen
    Tom Mullen
    Vice President of Operations & Product Development